All News
Filter News
Found 216 articles
-
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
5/26/2021
KAHR and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR's lead anti-CD47 candidate, DSP107, in blood cancers.
-
New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
5/19/2021
Results from a new integrated analysis including data from the MELTEMI Phase III open-label extension trial showed FASENRA® was well-tolerated for up to five years, with a long-term safety profile consistent with previous Phase III trials in adult patients with severe asthma.
-
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.
5/13/2021
Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, announced the appointment of Ciara Kennedy, Ph.D., M.B.A. to its board of directors.
-
Adverum Reports First Quarter 2021 Results
5/6/2021
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, reported financial results for the first quarter ended March 31, 2021.
-
Patients without diabetes who develop COVID-19 may be at a higher risk of actually developing diabetes following recovery, recent study claims.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
5/1/2021
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced new long-term data from the OPTIC clinical trial of ADVM-022 single intravitreal injection gene therapy in patients requiring frequent anti-VEGF injections for their neovascular or wet age-related macular degeneration.
-
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
4/28/2021
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME)
-
Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas
4/22/2021
Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has completed enrollment for its Phase 1 clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with immune checkpoint inhibitor Opdivo® (nivolumab) and standard of care radiation therapy, as well as temozolomide for patients with methylated MGMT promoters
-
Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases
4/22/2021
Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists
-
Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
4/13/2021
Candel Therapeutics, a clinical-stage biotechnology company developing novel immune-based cancer therapeutics, announced the initial formation of its Research Advisory Board with the appointment of James Allison, Ph.D., Henry Brem, M.D., Roy S. Herbst, M.D., Ph.D., Elizabeth Jaffee, M.D., Philip Kantoff, M.D., and Padmanee Sharma, M.D., Ph.D., who will join existing scientific advisor and board member Edward Benz, M.D.
-
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
4/12/2021
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced data were presented from its lead program AMX-818 (HER2-XPAT), at the AACR Annual Meeting.
-
Candel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
4/9/2021
Candel Therapeutics, a clinical-stage biotechnology company, developing novel immune-based cancer therapeutics, today announced the appointment of Chris Matheny, PharmD, Ph.D., as vice president, development leader.
-
KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy
4/1/2021
KAHR adds two preclinical products, DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein, to its pipeline
-
XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing
3/23/2021
XtalPi, an artificial intelligence drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to 'Drugging the Undruggable®' disease targets.
-
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
2/24/2021
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database evaluating RGN-259
-
Currently, research is still ongoing with regards to the link between COVID and POTS. However, this increasing number of cases and the unfamiliarity of COVID's long-lasting effects leave a lot more for the researchers to unmask.
-
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South AfricaTYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigens
2/12/2021
Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
-
Global superficial radiation therapy systems market size to garner substantial returns through 2025
1/19/2021
The latest research report on ‘global superficial radiation therapy systems market’ evaluates this industry vertical in terms of the revenue and volume, considering the historical data from 2015-2019 and forecast period as 2020-2025.
-
U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP
1/13/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite™ Trabecular Micro-Bypass System